Abstract:
본 발명은 탱자로부터 분리한 8-메톡시소랄렌을 포함하는 알츠하이머 예방 또는 치료용 조성물 및 상기 화합물의 분리방법에 관한 것으로, 더욱 상세하게는 탱자를 에탄올로 추출하여 추출물을 제조하고 상기 추출물을 헥산, 클로로포름, 에틸 아세테이트의 유기용매로 분획하여 분획물을 얻은 다음 이로부터 8-메톡시소랄렌을 분리하는 방법 및 상기 분리된 화합물을 유효성분으로서 함유함으로써 뇌 신경세포 함유 아세틸콜린 에스터라아제 저해능을 나타내어 알츠하이머병을 예방 또는 치료시킬 수 있는 조성물에 관한 것이다. 탱자, 추출물, 용매분획, 8-메톡시소랄렌, 알츠하이머 병, 아세틸콜린 에스터라아제 저해능, AChE 저해능
Abstract:
본 발명은 뇌 신경 세포 보호물질을 포함하는 질경이 추출물을 포함하는 퇴행성 신경 질환의 예방 또는 치료용 조성물에 관한 것이다. 보다 구체적으로, 뇌 신경 세포 보호물질로서 4-비닐-2-메톡시페놀을 포함하고, 산화적 스트레스(oxidative stress) 유발을 감소시키며 세포 활성(cell viability)을 증대시킬 뿐만 아니라 치매 모델 동물실험의 대안행동(alternative behavior) 및 스텝쓰루 레턴시(step through latency) 수동회피검사에서 기억 학습 능력을 유지시키는 질경이 추출물이 포함된 인체에 무해한 퇴행성 신경 질환의 예방 또는 치료용 조성물에 관한 것이다. 질경이 추출물, 아밀로이드 베타 펩타이드-유도 산화적 스트레스, 퇴행성 신경 질환
Abstract:
A composition comprising palmitic acid is provided to inhibit the oxidative stress induced by amyloid beta peptide excellently and secure excellent cell survival rate, thereby being usefully used for preventing or treating Alzheimer's disease. A pharmaceutical composition for preventing or treating Alzheimer's disease comprises palmitic acid which is obtained by extracting Gardenia jasminoides with water, alcohol or a mixture of water and alcohol, filtering the extract, concentrating the filtrate under reduced pressure and then freeze-drying the concentrate. A food composition useful for preventing Alzheimer's disease comprises palmitic acid extracted and isolated from Gardenia jasminoides.
batatas ) 추출물 또는 그로부터 분리된 2,4-다이-털트-뷰틸페놀(2,4-di-tert-butylphenol)을 포함하는 뇌 질환 예방 및 치료용 조성물에 관한 것으로, 상기 조성물은 알츠하이머 등의 뇌질환에 대해 우수한 효과를 발휘한다. 고구마, 아밀로베타 펩티드, 알츠하이머, 2,4-다이-털트-뷰틸페놀
Abstract:
PURPOSE: A nervous system disease prevention or treatment composition containing pomegranate extracts is provided to reduce the oxidative stress induction, and to enhance the cell activation. CONSTITUTION: A nervous system disease prevention or treatment composition contains pomegranate extracts. The nervous system disease is a disease which induces the neuronal cell damage by the amyloid beta peptide-inducing oxidative stress. The nervous system disease is alzheimer disease. The pomegranate extracts are obtained by ethanol. The nervous system disease prevention or treatment composition contains 2,4-bis(1,1-dimethylethyl)-phenol which is extracted from the pomegranate extracts.
Abstract:
본 발명은 뇌 신경 세포 보호물질을 포함하는 석류 추출물을 포함하는 뇌 신경 질환의 예방 또는 치료용 조성물에 관한 것이다. 보다 구체적으로, 뇌 신경 세포 보호물질로서 2,4-비스(1,1-디메틸에틸)-페놀(2,4-bis(1,1-dimethylethyl)-phenol)을 포함하고, 산화적 스트레스(oxidative stress) 유발을 감소시키며 세포 활성(cell viability)을 증대시킬 뿐만 아니라 치매 모델 동물실험의 대안행동(alternative behavior) 및 스텝 쓰루 레턴시(step through latency) 수동회피검사에서 기억 학습 능력을 유지시키는 석류 추출물이 포함된 인체에 무해한 뇌신경 질환의 예방 또는 치료용 조성물에 관한 것이다. 석류, 2,4-bis(1,1-dimethylethyl)-phenol, 아밀로이드 베타 펩티드(amyloid β peptide (Aβ)), 산화적 스트레스, 알츠하이머
Abstract:
PURPOSE: A composition containing Ipomoea batatas extract or 2,4-di-terbutylphenol for preventing and treating brain diseases is provided to ensure an effect for Alzheimer's disease. CONSTITUTION: A pharmaceutical composition for preventing and treating brain diseases contains Ipomoea batatas extract or fraction thereof as an active ingredient. The Ipomoea batatas extract is isolated using water, organic solvent, or mixture solvent thereof. The fraction is a water fraction, hexane fraction, chloroform fraction, or ethyl acetate fraction. The brain diseases are Alzheimer's diseases, senile dementia, vascular dementia, Huntington`s chorea, Parkinson's disease, migraine, or depression. A pharmaceutical composition for preventing and treating brain diseases contains 2,4-di-tert-butylphenol isolated from the Ipomoea batatas extract or pharmaceutically acceptable salt thereof.
Abstract:
PURPOSE: A composition containing 8-methoxypsoralen isolated from Poncirus trifoliate is provided to suppress acetylcholine esterase and prevent or treat Alzheimer disease. CONSTITUTION: A composition for preventing or treating Alzheimer disease contains 8-methoxypsoralen as an active ingredient. The 8-methoxypsoralen is isolated from Poncirus trifoliate. The composition for preventing or treating Alzheimer disease is pharmaceutical composition or food composition. A method for isolating 8-methoxypsoralen from Poncirus trifoliate comprises: a step of preparing ethanol extract from Poncirus trifoliate; a step f performing reflux extraction of the Poncirus trifoliate ethanol extract using hexane, chloroform, and ethyl acetate to obtain each solvent fraction; a step of performing silica gel column chromatography; and a step of isolating through HPLC.
Abstract:
PURPOSE: A composition containing Plantago asiatica for preventing or treating neurodegenerative diseases is provided to reduce oxidative stress and enhance cell viability. CONSTITUTION: A pharmaceutical composition for preventing or treating neurodegenerative diseases contains Plantago asiatica extract. The disease is Alzheimver disease. The Plantago asiatica extract is isolated using ethanol extract. A pharmaceutical composition for preventing or treating neurodegeneratibe disesases contains 4-vinyl-2-methoxynol. A method for isolating the 4-vinyl-2-methoxynol comprises: a step of fractioning the extract with other organic solvent to obtain fraction; a step of passing the fraction through an open silica gel column to obtain brain-damaged suppression activity; and a step of performing HPLC.
Abstract:
The extract of Pueraria thunbergiana or a low molecular weight flavonoid extracted therefrom is provided to activate choline acetyltransferase in brain nerve cells, so that it is useful for preventing or treating brain nerve disease. A composition for activating choline acetyltransferase in brain nerve cells comprises the extract of Pueraria thunbergiana as an effective ingredient, wherein the extract of Pueraria thunbergiana is prepared with methanol or ethanol. The low molecular weight flavonoid extracted from the extract of Pueraria thunbergiana is 4',7-dihydroxyisoflavone(daidzein), wherein low molecular weight flavonoid is purified by (i) extracting dried Pueraria thunbergiana with methanol or ethanol, (ii) fractionating the methanol or ethanol extract with hexane, chloroform and ethylacetate sequentially, (iii) subjecting the ethylacetate fraction to first and second open silica gel column, (iv) subjecting the active fraction to thin layer chromatography, and (v) subjecting the active fraction to high pressure liquid chromatography.